Best Growth Hormone Peptide (2026): Ranked & Compared

Last updated 18 June 2026. Educational content, not medical advice. Growth hormone peptides are not FDA-approved for general anti-aging or body composition use. Talk to a licensed clinician before starting any peptide protocol.

Short answer: For most people seeking growth hormone optimization through a licensed clinic in 2026, the CJC-1295 (no-DAC) plus Ipamorelin stack is the strongest practical choice, combining a synergistic two-receptor hit, a clean hormonal profile, and reasonable monthly costs of $199 to $399. Tesamorelin holds the highest evidence tier as the only FDA-approved GHRH analog in this class, but its prescription pathway is narrow. Sermorelin remains the safest and cheapest entry point. The one you should actually be on depends on your baseline IGF-1, your goals, and whether a licensed clinician agrees.

Why does choosing the wrong growth hormone peptide cost more than the wrong choice?

Most people who search “best growth hormone peptide” are not trying to win a bodybuilding show. They are 35 to 60 years old, feeling the low-grade erosion that comes with declining GH output: sleep that never fully restores, body fat that concentrates around the middle no matter what the diet looks like, recovery that lags a week behind what training demands, and an IGF-1 number their doctor calls “technically normal” but that sits at the bottom quartile of the reference range.

Growth hormone production peaks in the late teens and drops roughly 14% per decade after age 30. By 60, most adults produce a fraction of their youthful GH output, with IGF-1 levels that can fall below 100 ng/mL in people who once ran at 250 or higher. That trajectory is not pathology in the clinical sense. But it is the biological substrate the entire growth hormone peptide category is built around.

The mistake is treating all GH peptides as interchangeable. They are not. They work through different receptors, produce different pulse shapes, carry different side effect profiles, and have dramatically different regulatory statuses. Choosing by price or forum reputation, rather than by mechanism and clinical fit, is how people either waste months on a compound too weak for their baseline or land on one that drives cortisol and prolactin upward while only modestly lifting GH.

How do growth hormone peptides actually work?

Growth hormone is not released in a steady stream. It fires in pulses, the largest of which occurs during slow-wave sleep, and each pulse is triggered by two competing signals from the hypothalamus: growth hormone-releasing hormone (GHRH), which opens the gate, and ghrelin (or ghrelin mimetics), which pulls the trigger.

Every GH peptide works by amplifying one or both of those signals. This creates two distinct drug classes:

GHRH analogs (sermorelin, CJC-1295, tesamorelin) mimic or extend the GHRH signal. They “load the cannon” by priming the pituitary somatotrophs to release GH but still require the natural ghrelin trigger to fire the pulse.

Growth hormone-releasing peptides / ghrelin mimetics (ipamorelin, GHRP-2, GHRP-6, hexarelin, MK-677) bind the ghrelin receptor and independently trigger GH release. They fire the pulse but do not prime the cannon as effectively without the GHRH signal backing them.

The key insight most product pages skip: when a GHRH analog and a ghrelin mimetic are given together, they act on two independent receptor systems simultaneously. The synergistic effect on GH release exceeds what either compound achieves alone by 2 to 10 fold, which is the entire clinical rationale behind combination stacks.

This is not marketing. A 2006 clinical study on CJC-1295 demonstrated approximately 7.5-fold increases in GH pulse amplitude compared to placebo in a 65-person cohort, with IGF-1 rising 1.5 to 3-fold above baseline and sustaining that elevation for 6 or more days after a single injection. The combination principle is the mechanism.

The five main GH peptides, ranked by evidence and clinical fit

Tesamorelin: the gold standard if you qualify

Tesamorelin is a stabilized analog of GHRH with a trans-3-hexenoic acid group attached that prevents rapid enzymatic degradation. It is the only GHRH analog in this category with FDA approval, granted in 2010 as Egrifta (and later Egrifta SV) for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Two Phase 3 randomized controlled trials published in The Lancet demonstrated 15 to 18% visceral adipose tissue (VAT) reduction at 26 weeks, with effects sustained at 52 weeks.

Personally, this is the compound I find most compelling on paper, because it is the only one where regulatory reviewers actually had to see randomized placebo-controlled data before saying yes. That is a different evidentiary foundation from everything else on this list.

The limitation: the FDA indication is specific, and off-label prescribing for general body composition or anti-aging purposes exists in a regulatory grey zone. Clinics that prescribe it for longevity applications do so under physician discretion, and costs run higher than sermorelin or the CJC/Ipamorelin stack, typically $250 to $500 per month depending on the protocol.

CJC-1295 (no-DAC) plus Ipamorelin: the clinical workhorse

This is the most prescribed GH peptide combination at US telehealth longevity clinics in 2026, and the clinical rationale is sound. CJC-1295 without DAC (also called Modified GRF 1-29) is a GHRH analog with a half-life of 30 to 60 minutes that produces a clean, short-acting pulse mimicking the body’s natural nocturnal GH pattern. Ipamorelin is a selective ghrelin receptor agonist, the most targeted GHRP available, that triggers a GH pulse without raising cortisol, prolactin, or ACTH.

The combination hits both receptor pathways simultaneously. The result is a GH pulse 2 to 10 times greater than either compound generates alone, timed to coincide with sleep for maximum physiological alignment.

What differentiates ipamorelin from other GHRPs is selectivity. GHRP-6 and GHRP-2 both produce cortisol and prolactin elevation alongside the GH spike. Hexarelin is even more potent but carries significant desensitization risk and raises cortisol measurably. Ipamorelin does none of that. It targets the GH axis and leaves the stress-hormone axis alone. For anyone running a 3 to 6 month protocol, that difference in selectivity matters far more than the modest potency advantage of the more aggressive GHRPs.

Realistic timelines from clinical experience at providers like Wittmer Rejuvenation Clinic and Perfect Balance: improved sleep quality appears first, usually within 2 to 4 weeks. Visible body composition shifts, leaner midsection, improved muscle fullness, take 6 to 12 weeks. Most patients on supervised protocols lose 10 to 20 pounds of fat and gain 3 to 8 pounds of lean mass over 4 to 6 months, though individual results vary substantially by baseline metabolic state, training consistency, and starting IGF-1.

CJC-1295 with DAC: the weekly-injection version with a tradeoff

CJC-1295 with DAC attaches a Drug Affinity Complex (DAC) that allows the peptide to covalently bind to serum albumin, extending its half-life from roughly 30 minutes to approximately 8 days. Once or twice weekly injections replace daily administration.

The convenience is real. The tradeoff is also real: the prolonged half-life converts pulsatile GH release into a sustained low-level elevation, a “GH bleed” rather than a physiological pulse. Some clinicians argue this blunts the natural feedback loop and may reduce the body’s sensitivity to endogenous GHRH over time. Most modern protocols prefer the no-DAC version specifically because the pulse pattern matters, not just the average elevation.

Do not let anyone sell you CJC-1295 with DAC as the “stronger” version. It is the longer-lasting version, which is a different thing entirely.

Sermorelin: the starter lane

Sermorelin is a 29-amino acid fragment of GHRH, specifically the first 29 residues, and was actually the first synthetic GHRH analog to reach clinical use, with an FDA approval history in pediatric growth hormone deficiency before the branded GHRH products took over that indication. It has the shortest half-life of the group (10 to 20 minutes) and the weakest GH stimulation effect per unit.

Why it still matters: it is the most established, the cheapest (typically $96 to $225 per month through telehealth providers like IvyRx or Strut Health), and the most widely available on licensed telehealth platforms because its regulatory history is the cleanest. For someone who wants to start cautiously, confirm their response to a GHRH analog, and build baseline data before moving to the more aggressive combination stacks, sermorelin is the sensible first step.

Personally, I would not stay on sermorelin as the ceiling. The step up to the CJC-1295/Ipamorelin combination adds the ghrelin receptor component that sermorelin alone cannot provide, and the synergistic effect is too well-documented to ignore.

MK-677 (Ibutamoren): the oral outlier and its specific risks

MK-677 is not a peptide in the traditional sense. It is a non-peptide ghrelin mimetic developed by Merck Research Laboratories, and its key structural difference from injectable GHRPs is oral bioavailability. It is swallowed, not injected, which makes it attractive to anyone who wants the GH-stimulating effect without needles.

The mechanism is effective. MK-677 raises both GH and IGF-1, improves slow-wave sleep depth (which is often the first benefit users notice), and has a 24-hour half-life that means once-daily dosing. A published 2-year study in older adults showed sustained increases in IGF-1 of roughly 40% from baseline.

The risks are specific and non-trivial. The ghrelin receptor activity drives significant appetite stimulation, water retention, and, most importantly for anyone with metabolic risk, meaningful insulin resistance and elevated fasting glucose. These effects are not rare or mild in susceptible individuals. Anyone with pre-diabetes, elevated fasting insulin, or existing metabolic syndrome should treat MK-677 as a serious contraindication, not a minor precaution.

MK-677 is also not FDA-approved for any indication. It is classified as a non-approved investigational compound. WADA bans it in and out of competition under Category S2 as a growth hormone secretagogue. Despite appearing in supplement-adjacent marketing, this is not a nutraceutical.

Head-to-head comparison table

Peptide	Mechanism class	Route	Half-life	GH pulse pattern	Cortisol/prolactin effect	FDA approval	Typical monthly cost (telehealth)	Best for
Tesamorelin	GHRH analog	Injection	~30 min	Pulsatile	None	Yes (narrow indication)	$250–$500	Visceral fat reduction, highest evidence
CJC-1295 No-DAC + Ipamorelin	GHRH analog + GHRP	Injection	30–60 min	Pulsatile, synergistic	None (Ipamorelin selective)	No	$199–$399	Body composition, sleep, overall GH optimization
CJC-1295 with DAC	GHRH analog (long)	Injection	~8 days	Continuous bleed	None	No	$150–$350	Convenience-first users; less physiological
Sermorelin	GHRH fragment	Injection	10–20 min	Mild pulsatile	None	Former pediatric approval	$96–$225	Conservative starters, lowest cost
MK-677 / Ibutamoren	Ghrelin mimetic (oral)	Oral	~24 hours	Sustained elevation	Appetite up, insulin resistance risk	No	$60–$150 (grey market)	Research; contraindicated in metabolic syndrome
GHRP-6 / GHRP-2	GHRP	Injection	15–30 min	Pulsatile	Cortisol + prolactin elevated	No	Research only	Not preferred for sustained use
Hexarelin	GHRP (potent)	Injection	~60 min	Strong pulse, desensitizes	Cortisol + prolactin elevated	No	Research only	Potency at cost of selectivity

The CJC-1295 with DAC vs. No-DAC confusion (and why it matters)

This is the most common point of confusion in the growth hormone peptide space, and getting it wrong changes the character of the entire protocol.

CJC-1295 without DAC and CJC-1295 with DAC share the same amino acid sequence. The DAC modification adds a lysine-maleimide group that lets the peptide bind covalently to albumin in the bloodstream, creating a slow-release reservoir. That single structural difference extends the half-life from 30 minutes to 8 days.

The consequence is a shift from pulsatile to continuous GH stimulation. Most sports medicine and longevity clinicians now prefer No-DAC specifically because mimicking the body’s natural nocturnal GH pulse is the design intent. A flat 8-day elevation is pharmacologically more like exogenous HGH than like physiological growth hormone secretagogue therapy, which is the opposite of what the category is supposed to offer.

The forums still debate this, but the clinical direction has largely settled on No-DAC for the precise reason that maintaining the pulsatile pattern preserves the body’s sensitivity to its own GHRH over time. DAC is useful when patients struggle with daily injections. That is the real tradeoff: compliance versus physiology.

Who should actually consider growth hormone peptide therapy?

Growth hormone peptides are optimization tools, not rescue medications. The profile of someone likely to see meaningful benefit, rather than a modest IGF-1 bump and an expensive monthly bill, tends to cluster around a few characteristics:

Confirmed low-normal IGF-1. The strongest predictor of response magnitude is baseline IGF-1 level. Adults with IGF-1 below 150 ng/mL (particularly under 120 ng/mL) have more room to benefit than those already sitting at 220 to 250 ng/mL. If your baseline IGF-1 is already high-normal, the ceiling effect means you may be paying for modest changes.

Sleep-related recovery complaints. GH peptides work primarily through the nocturnal pulse. The benefits that show up earliest and most reliably are sleep quality improvements, faster muscular recovery, and reduced morning stiffness. If your main complaint is purely cosmetic or performance-related without any sleep deficit, temper expectations accordingly.

Metabolic baseline that tolerates the protocol. Anyone with pre-diabetes or elevated fasting glucose should avoid MK-677 entirely and should not start any GH peptide stack without confirmed baseline metabolic labs and physician oversight. GH stimulation has dose-dependent effects on insulin sensitivity, and starting blind is avoidable negligence.

Age over 35 with documented decline. The clinical rationale is sound for adults over 35 with objective evidence of low GH output. Using these tools in a 28-year-old with normal IGF-1 looking for “optimization gains” is a different risk-benefit equation with weaker justification.

What does the regulatory landscape look like in 2026?

The regulatory ground under growth hormone peptides has been the most active it has ever been, and the direction matters for anyone planning a protocol.

Tesamorelin and sermorelin have the cleanest histories: both were FDA-approved in prior eras for specific indications and can be prescribed off-label through licensed physicians.

CJC-1295 and Ipamorelin occupy the current grey-to-legal transition zone. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23 to 24, 2026 to vote on whether seven peptides, including BPC-157, TB-500, Semax, and Epitalon, should return to the 503A Category 1 list (permitted for compounding). CJC-1295 and Ipamorelin are already being prescribed through legitimate compounding channels at many clinics; the July meeting addresses the broader batch of restricted compounds.

What this means practically: a compliant licensed clinic prescribing sermorelin or CJC-1295/Ipamorelin stacks today is operating in a well-defined, lawful channel. A vendor selling any of these compounds in vials labeled “research use only,” without a prescription, is not.

Do not believe anyone telling you the “research use only” label is a technicality that washes off. It is the legal fiction that makes the entire grey-market exist, and it transfers 100% of the legal and safety risk to you, the buyer, the moment you use it.

The IGF-1 number that should stop you from starting

Here is something clinicians note that almost no product page mentions: IGF-1 levels above 250 to 280 ng/mL are not a goal, they are a warning.

Elevated IGF-1, whether from exogenous HGH or from aggressive peptide stacking, is associated in long-term epidemiological data with accelerated cellular proliferation risk. Legitimate protocols set an IGF-1 ceiling, typically 200 to 250 ng/mL, and monitor at 8 to 12 week intervals to confirm the patient has not exceeded it.

Any clinic or vendor that offers growth hormone peptides without requiring baseline and follow-up IGF-1 monitoring is telling you something important about how carefully it is actually managing your health. That is not a minor omission.

The monitoring cadence matters in the other direction too. If you start a CJC-1295/Ipamorelin protocol at a baseline IGF-1 of 95 ng/mL and see no movement after 12 weeks, you need to troubleshoot: injection technique, timing relative to meals, reconstitution quality, or the possibility that the compounding pharmacy’s product is not what the label claims.

The myth of the “HGH-equivalent” peptide stack

Myth: a high-dose CJC-1295/Ipamorelin stack produces results equivalent to pharmaceutical HGH injections.

Reality: it does not. Synthetic HGH (somatropin, Norditropin, Genotropin) delivers a fixed exogenous dose that bypasses the pituitary entirely. A peptide stack stimulates the pituitary to release more of its own GH, which means the ceiling is set by the patient’s pituitary reserve, not the dose.

For adults over 40 with significantly reduced pituitary reserve, the response to secretagogues is lower than it would have been at 25, because the pool of somatotrophs available to stimulate is smaller. That is not a reason to avoid peptides, the risk and cost profile of exogenous HGH ($1,200 to $5,000 per month, with a direct suppression of the HPG axis) is dramatically worse at equivalent dose. But it is a reason to set expectations correctly.

The sweet spot for peptide therapy is precisely the people who still have sufficient pituitary reserve to respond, but whose natural GH output has declined enough from their youthful baseline to make stimulation worthwhile. That is a real and large population. It is not everyone who wants to feel 25 again.

FAQ

What is the best growth hormone peptide for body composition?

The CJC-1295 No-DAC plus Ipamorelin combination is the most widely used and best-supported combination for body composition goals including fat reduction and lean mass support. The two-receptor synergy produces 2 to 10 times greater GH pulses than either alone, and Ipamorelin’s selectivity means no unwanted cortisol or prolactin elevation. Results take 6 to 12 weeks to appear visibly, with most supervised patients seeing measurable abdominal fat reduction and improved muscle quality over a 4 to 6 month protocol.

Is sermorelin or ipamorelin CJC-1295 better?

They solve different parts of the same problem. Sermorelin acts on the GHRH receptor alone and produces mild pulsatile GH stimulation at a lower cost ($96 to $225 per month). The CJC-1295/Ipamorelin stack hits both the GHRH receptor and the ghrelin receptor, producing synergistically stronger GH pulses and adding the sleep and recovery benefits specific to ghrelin receptor activity. For someone who wants the best results and can access a clinic that prescribes it, the combination outperforms sermorelin. For someone starting conservatively or working within a tighter budget, sermorelin is the sensible first step.

What is the difference between CJC-1295 with DAC and without DAC?

Both share the same amino acid sequence but differ by one structural attachment. The DAC (Drug Affinity Complex) modification extends the half-life from 30 minutes to approximately 8 days by allowing the peptide to bind albumin in the bloodstream. CJC-1295 No-DAC produces a short, sharp GH pulse mimicking natural physiology. CJC-1295 with DAC produces a prolonged, continuous GH elevation more similar to exogenous HGH. Most clinicians in 2026 prefer No-DAC specifically because the pulsatile pattern is the design intent of growth hormone secretagogue therapy.

Is MK-677 safer than injectable GH peptides?

Not necessarily, though it avoids injections. MK-677 is orally active and produces sustained IGF-1 elevation and improved sleep, but its ghrelin receptor mechanism drives significant appetite increase, water retention, and, most importantly, insulin resistance and elevated fasting glucose. These are well-documented risks that are absent or minimal with injectable GHRH/GHRP combinations like CJC-1295/Ipamorelin. Anyone with any metabolic risk factors should treat MK-677 with specific caution and should not start without baseline fasting glucose, insulin, and HbA1c data.

How much does growth hormone peptide therapy cost in 2026?

Sermorelin through telehealth providers runs $96 to $225 per month. The CJC-1295/Ipamorelin combination through licensed clinics runs $199 to $399 per month, typically bundling the prescription, compounded medication, and follow-up monitoring. Tesamorelin for off-label use runs $250 to $500 per month. Synthetic HGH (somatropin) runs $1,200 to $5,000 per month and is almost never covered by insurance for optimization purposes. None of these are covered by insurance for anti-aging or body composition indications.

Do I need labs before starting a GH peptide protocol?

Yes, and any provider that says otherwise is not operating to clinical standard. Minimum baseline labs for GH peptide therapy include IGF-1, fasting glucose, fasting insulin, a complete metabolic panel (CMP), and a lipid panel. MK-677 users should add HbA1c given the insulin resistance risk. IGF-1 should be rechecked at 8 to 12 weeks to confirm response, and should not be allowed to exceed 250 ng/mL. Without baseline labs, you cannot measure whether the protocol is working, cannot identify early adverse metabolic signals, and have no floor to compare results against.

Can I get growth hormone peptides without a prescription?

Sermorelin, CJC-1295, Ipamorelin, and Tesamorelin require a prescription when obtained from a licensed compounding pharmacy in the US, which is the only way to get them legally for human use. Research-grade vials sold online with “for laboratory research only” labels are not a legal alternative for personal use. The FDA crackdown of 2024 to 2026 removed major grey-market suppliers, and the ones still standing carry the same fundamental risks: no identity verification, no clinical oversight, no accountability if the purity is not what the label claims.

What Is the Best Growth Hormone Peptide? A Clinician-Backed Comparison for 2026